approval
saveTREMFYA (GUSELKUMAB) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalTREMFYA (GUSELKUMAB) — FDA approvalSep 26, 2025 · 370d ago
- approvalTREMFYA (GUSELKUMAB) — FDA approvalSep 26, 2025 · 370d ago
- approvalTREMFYA (GUSELKUMAB) — FDA approvalSep 19, 2025 · 377d ago
- approvalTREMFYA (GUSELKUMAB) — FDA approvalJun 17, 2025 · 471d ago
- approvalTREMFYA (GUSELKUMAB) — FDA approvalMar 25, 2025 · 555d ago
- approvalTREMFYA (GUSELKUMAB) — FDA approvalMar 20, 2025 · 560d ago
- approvalTREMFYA (GUSELKUMAB) — FDA approvalJun 29, 2023 · 1190d ago
- approvalTREMFYA (GUSELKUMAB) — FDA approvalJul 13, 2020 · 2271d ago
same company · ±60 days · 6
- approvalamivantamab: RYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalSep 19, 2024
- approvallazertinib mesylate: LAZCLUZE (LAZERTINIB MESYLATE) — FDA approvalAug 19, 2024
- approvalamivantamab: RYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalAug 19, 2024
- approvalerdafitinib: BALVERSA (ERDAFITINIB) — FDA approvalOct 9, 2024
- approvalapalutamide: ERLEADA (APALUTAMIDE) — FDA approvalAug 2, 2024
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalJul 30, 2024
comments(0)
5-min edit window · permanent after that